Ferrer has entered a collaboration and license agreement with Prilenia for the commercialization and co-development of Pridopidine, aimed at treating Huntington's Disease in multiple international regions.

Target Information

Ferrer, a B Corp pharmaceutical company based in Barcelona, Spain, specializes in rare neurological diseases, while Prilenia Therapeutics B.V. is a clinical-stage biotech firm focused on developing therapies for neurodegenerative disorders. The two companies have recently entered into a collaboration and license agreement that allows Ferrer to develop, manufacture, and commercialize Pridopidine across diverse regions, including Europe, the Middle East, North Africa, Southern Africa, Central and South America, and the Commonwealth of Independent States.

Pridopidine is an orally administered sigma-1 receptor agonist aimed at addressing neuroprotective mechanisms often disrupted in neurodegenerative diseases. It holds significant potential for the treatment of Huntington's Disease (HD), a rare genetic disorder that currently has a vast unmet medical need. The drug has undergone extensive testing, with over 1,700 participants in clinical studies and a long-term safety profile established over seven years, showing a tolerability comparable to placebo at therapeutic doses.

Industry Overview in Spain

The pharmaceutical industry in Spain is pivotal to the European healthcare landscape, characterized by a growing emphasis on innovative therapies, especially for rare diseases. The Spanish government has established policies that incentivize research and de